cap raising, page-9

Batroc

Then you are assuming that:

- there will be no farm-in type deal announced for the hugely valuable HU91 and follow on antibody trial.

- Quest diagnostics will dump it's internal proteomic programs and purchase NSCLC tests from competitors next year (just as its own test is cleared for market).

- Currently strong Evolis sales will collapse;

- AIM trials next year will fail;

- Indicative results from the Japanese MK Elisa trials will turn from positive to negative;

- There is no actual demand found for a better Mesothelioma diagonstic test;

- The positive reported results MK antibodies have had in treating bone cancer were just a case of academic fraud;

- US research and diagnostic houses (such as Quest) are not actually purchasing MK Elisas for further evaluation;

- The FDA will fail to attend a scheduled meeting with CDY and several reseach and diagnostics companies;

- CX bladder will not become a gold standard bencmark to be followed.

- The dozen or so companies in consultation with Maria will leave King Street unimpressed;


I can't say that any or all of these failures won't happen. But nor can anyone say that they will.

cheers